Sarah Coakeley1, Antonio P Strafella. 1. aMorton and Gloria Shulman Movement Disorder Unit and Edmond J. Safra Program in Parkinson Disease, Toronto Western Hospital, University Health Network bResearch Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health cDivision of Brain, Imaging, and Behaviour - Systems Neuroscience, Toronto Western Research Institute, University Health Network, University of Toronto, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: This review examines the current literature on tau imaging in atypical parkinsonian disorders and other tauopathies. RECENT FINDINGS: There are a number of tau PET radiotracers that have demonstrated promising preliminary results in atypical parkinsonian disorders, such as progressive supranuclear palsy and corticobasal degeneration. These radiotracers were capable of selectively labeling tau in vitro and in vivo, with high affinity. Other radiotracers tested more extensively in patients with Alzheimer's disease have also been able to successfully image tau deposition. SUMMARY: The development of tau radioligands for PET has led to the current testing of these tracers in clinical studies, many of which concentrate on patients with Alzheimer's disease. Atypical parkinsonian disorders such as progressive supranuclear palsy and corticobasal degeneration are now being investigated as well. These disorders can be very difficult to diagnose, because of their clinical overlap with other parkinsonian disorders. Imaging tau using PET could serve as a diagnostic biomarker for these tauopathies and provide a means of assessing treatment that targets tau burden.
PURPOSE OF REVIEW: This review examines the current literature on tau imaging in atypical parkinsonian disorders and other tauopathies. RECENT FINDINGS: There are a number of tau PET radiotracers that have demonstrated promising preliminary results in atypical parkinsonian disorders, such as progressive supranuclear palsy and corticobasal degeneration. These radiotracers were capable of selectively labeling tau in vitro and in vivo, with high affinity. Other radiotracers tested more extensively in patients with Alzheimer's disease have also been able to successfully image tau deposition. SUMMARY: The development of tau radioligands for PET has led to the current testing of these tracers in clinical studies, many of which concentrate on patients with Alzheimer's disease. Atypical parkinsonian disorders such as progressive supranuclear palsy and corticobasal degeneration are now being investigated as well. These disorders can be very difficult to diagnose, because of their clinical overlap with other parkinsonian disorders. Imaging tau using PET could serve as a diagnostic biomarker for these tauopathies and provide a means of assessing treatment that targets tau burden.
Authors: Nobuyuki Okamura; Shozo Furumoto; Michelle T Fodero-Tavoletti; Rachel S Mulligan; Ryuichi Harada; Paul Yates; Svetlana Pejoska; Yukitsuka Kudo; Colin L Masters; Kazuhiko Yanai; Christopher C Rowe; Victor L Villemagne Journal: Brain Date: 2014-03-27 Impact factor: 13.501
Authors: David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb Journal: J Alzheimers Dis Date: 2013 Impact factor: 4.472
Authors: Victor L Villemagne; Michelle T Fodero-Tavoletti; Colin L Masters; Christopher C Rowe Journal: Lancet Neurol Date: 2015-01 Impact factor: 44.182
Authors: Melissa J Armstrong; Irene Litvan; Anthony E Lang; Thomas H Bak; Kailash P Bhatia; Barbara Borroni; Adam L Boxer; Dennis W Dickson; Murray Grossman; Mark Hallett; Keith A Josephs; Andrew Kertesz; Suzee E Lee; Bruce L Miller; Stephen G Reich; David E Riley; Eduardo Tolosa; Alexander I Tröster; Marie Vidailhet; William J Weiner Journal: Neurology Date: 2013-01-29 Impact factor: 9.910
Authors: Melissa E Murray; Naomi Kouri; Wen-Lang Lin; Clifford R Jack; Dennis W Dickson; Prashanthi Vemuri Journal: Alzheimers Res Ther Date: 2014-01-02 Impact factor: 6.982
Authors: Matthias Brendel; Sonja Schönecker; Günter Höglinger; Simon Lindner; Joachim Havla; Janusch Blautzik; Julia Sauerbeck; Guido Rohrer; Christian Zach; Franziska Vettermann; Anthony E Lang; Lawrence Golbe; Georg Nübling; Peter Bartenstein; Katsutoshi Furukawa; Aiko Ishiki; Kai Bötzel; Adrian Danek; Nobuyuki Okamura; Johannes Levin; Axel Rominger Journal: Front Aging Neurosci Date: 2018-01-17 Impact factor: 5.750